For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.

Scientific Claim

In individuals with HIV and non-alcoholic fatty liver disease (NAFLD) taking integrase inhibitor (INSTI)-containing antiretroviral therapy, tesamorelin treatment for 12 months likely results in a 31% relative reduction in hepatic fat fraction compared to baseline, which is significantly greater than the placebo group's minimal change (absolute change: -4.9% vs -0.1%, p=0.015).

Original Statement

“the tesamorelin treated group saw a 31% relative reduction in HFF compared to baseline (p=0.006) which was significantly higher than in the placebo treated group (T:-4.9%, P:-0.1% absolute change p=0.015).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

The RCT design supports causal inference with probability verbs, and 'likely results in' appropriately reflects the reduced confidence due to unknown blinding status.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.

98%

For people with HIV and fatty liver on INSTI drugs, tesamorelin reduced liver fat by 31% compared to their starting point, which was a significant improvement. This finding is from the abstract summary - full study details were not available

96%

For people with HIV and fatty liver on INSTI drugs, tesamorelin lowered liver fat by 4.9% compared to almost no change (0.1%) in the placebo group, which was a significant difference. This finding is from the abstract summary - full study details were not available

96%

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

95%

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

94%